• Álvaro Contreras, Bruno Grassi, Daniela Alfaro, Felipe González, and Valeska Ortega.
• Departamento de Nutrición, Diabetes y Metabolismo, Pontificia Universidad Católica de Chile, Santiago, Chile.
• Rev Med Chil. 2019 Sep 1; 147 (9): 1093-1098.

BackgroundSodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new pharmacological alternative for the treatment of diabetes.AimTo report our experience with the use of this type of drugs in type 2 diabetics treated in an outpatient clinic.Material And MethodsWe selected 77 type 2 diabetic patients aged 59 ± 11 years (45 men) who started SGLT2i, based on the advice of their treating physician. We registered their demographic characteristics and changes in metabolic parameters, weight, blood pressure, albuminuria and adverse effects, during a follow-up of at least three months.ResultsWe observed a decrease of glycosylated hemoglobin A1c of 0.8 ± 1.14% (p < 0.01) and a weight decrease of 2.5 ± 2.24 kg (p < 0.01). The proportion of patients with a glycosylated hemoglobin A1c of less than 7% increased from 7.2% to 30.9% (p = 0.002). In addition, a relative decrease in albuminuria of 39.9% was observed (p = 0.07). The treatment was well tolerated with a rate of adverse effects of 21%, all of them being categorized as mild. Of these, most of them corresponded to genital mycotic infections.ConclusionsThe effects observed in this study are comparable and of similar magnitude to randomized studies of SGLT2i reported in the international literature.

13 keywords...

hide…